Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation

Blood. 2007 Oct 1;110(7):2779-80. doi: 10.1182/blood-2007-06-094508.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Fusion Proteins, bcr-abl / genetics*
  • Fusion Proteins, bcr-abl / metabolism
  • Harringtonines / therapeutic use*
  • Homoharringtonine
  • Humans
  • Interferon-alpha / therapeutic use*
  • Isoleucine / genetics
  • Isoleucine / metabolism
  • Kinetics
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Male
  • Mutation / genetics*
  • Salvage Therapy*
  • Tyrosine / genetics
  • Tyrosine / metabolism

Substances

  • Harringtonines
  • Interferon-alpha
  • Isoleucine
  • Tyrosine
  • Homoharringtonine
  • Fusion Proteins, bcr-abl